Pursuant to Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations And Disclosure REquirements) Regulations, 2015, we enclose herewith the summary of proceedings of Extraordinary ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries held an Extraordinary General Meeting on 11th August 2025 at 1:00 PM via video conferencing, chaired by Mr. Hemal Mehta, Chairman & Managing Director. The key item transacted was a Special Resolution seeking approval for the issuance of securities for an amount not exceeding INR 1,500 Crores, under Sections 23, 41, 42, 62(1)(c), 71, 179 and other applicable provisions of the Companies Act, 2013. The facility of remote e-voting and e-voting during the meeting was provided, with Mr. Vishal Manseta appointed as the Scrutinizer. Consolidated voting results are to be declared within two working days and shared with BSE and posted on the company's website. The meeting concluded at 1:20 PM with a vote of thanks.
The INR 1,500 Crore securities issuance proposal is a significant potential capital raise, which could lead to dilution for existing shareholders depending on whether it is a preferential allotment, private placement, or rights issue. The final structure will determine the impact on share price and ownership. Shareholders should watch for the voting results and the detailed terms of the issuance in upcoming disclosures.